Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin prophylaxis for COPD exacerbations in primary antibody deficiency
2011-004351-39Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) and Immunogenetic disorder comparing Azithromycin prophylaxis with Placebo (2 arms). Primary endpoints: Annual episodes of acute COPD exacerbations and Adverse events. Started Mar 2012; status: completed.
02
Drugs
azithromycin
03
Conditions
chronic obstructive pulmonary disease (COPD)Immunogenetic disorder
Beyond the preview
Go deeper on 2011-004351-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004351-39.